PH-1

NEW DRUGS FOR THE TREATMENT OF PRIMARY HIPEROXALURIA

 Coordinatore UNIVERSIDAD DE GRANADA 

 Organization address address: CUESTA DEL HOSPICIO SN
city: GRANADA
postcode: 18071

contact info
Titolo: Dr.
Nome: Monica
Cognome: Diaz-Gavilan
Email: send email
Telefono: -247602
Fax: -244769

 Nazionalità Coordinatore Spain [ES]
 Totale costo 45˙000 €
 EC contributo 45˙000 €
 Programma FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
 Code Call FP7-PEOPLE-2009-RG
 Funding Scheme MC-ERG
 Anno di inizio 2009
 Periodo (anno-mese-giorno) 2009-12-01   -   2013-11-02

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    UNIVERSIDAD DE GRANADA

 Organization address address: CUESTA DEL HOSPICIO SN
city: GRANADA
postcode: 18071

contact info
Titolo: Dr.
Nome: Monica
Cognome: Diaz-Gavilan
Email: send email
Telefono: -247602
Fax: -244769

ES (GRANADA) coordinator 45˙000.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

ph    active    biological    pharmacological    kidney    chaperones    synthesis    applicant    disease    endemic    therapy    life    oxalate    primary    protein    treatment    university    enzyme    agt    liver    misfolding   

 Obiettivo del progetto (Objective)

'Primary hiperoxaluria (PH-1) is a human genetic disease consisting on a deficiency of alanine-glyoxylateaminotransferase (AGT) activity in hepatocytes. This enzyme metabolizes glyoxylate and a lack of its activity leads to an excessive production of oxalate. Oxalate accumulation damages kidney and liver functions at first and other tissues and organs later. This disease is lethal and no effective pharmacological treatment exists nowadays; renal and hepatic transplants become necessary to preserve the life of the patients. Several mutations on AGT gene, leading to protein misfolding that avoids enzymatic activity, have been described as responsible for this disease. Our objective in this project is to develop an effective treatment for PH-1, based in a strategy of pharmacological stabilization of AGT. This novel approach is the state of the art for protein misfolding, and it is based in the use of pharmacological chaperones to recover protein active conformation. In this Memory we include the design, synthesis and biological evaluation of a series of chaperones for AGT. The synthesis has been designed following a Diversity Oriented Synthesis-like scheme, based on the knowledge of the recently described enzyme active site and it is an application of the skills that the applicant acquired during her postdoctoral stay at Cambridge University (UK) as a Marie Curie IEF-Fellow. The project is a multidisciplinary approach with a synthetic chemical part to be developed at the University of Granada, where the applicant is Assistant Lecturer, and a biological part to be developed during short stays at the University of La Laguna (Canary Islands, PH-1 endemic zone) in collaboration with Prof. Eduardo Salido, a specialist in PH-1. The project deals with a topic of interest in European Research as it faces the treatment of an “orphan disease” that is endemic in some regions of Europe, and it meets a part of the therapy not fully covered by the pharmaceutical industry'

Introduzione (Teaser)

Primary hyperoxaluria (PH-1) predominantly affects people between 1 and 25 years of age and there is no drug therapy available. Currently, the only effective treatment option for this life-threatening condition is a combined kidney and liver transplant.

Altri progetti dello stesso programma (FP7-PEOPLE)

NANOSENS (2009)

Electrochemical biosensors as new generation of biotechnological devices for food safety and quality monitoring

Read More  

LACTABLOCK (2012)

Design and synthesis of selective inhibitors of human lactate dehydrogenase 5 targeting the peculiar metabolism of glucose in tumours

Read More  

HIFI (2013)

Hybrid Fluorescence Optoacoustic Imaging

Read More